Example: Heart Attack

Search clinical trials for: Cytarabine

Total 1339 results

NCT04493164

Not yet recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia With Gene Mutations; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT04486391

Not yet recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT04475731

Not yet recruiting

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

Conditions: Philadelphia-Positive ALL; Acute Lymphoblastic Leukemia, in Relapse
NCT04446130

Recruiting

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Conditions: Induction Chemotherapy; Acute T-Lymphocytic Leukemia; T-cell Lymphoblastic Lymphoma Leukemia; T-cell/Myeloid Mixed Phenotype Acute Leukemia
NCT04425655

Not yet recruiting

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Conditions: Acute Myeloid Leukemia, Adult; AML; AML, Adult
NCT04415008

Not yet recruiting

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

Conditions: CEBPA Double Mutation; Acute Myeloid Leukemia
NCT04402723

Recruiting

Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML

Conditions: Acute Myeloid Leukemia (AML)
NCT04385290

Not yet recruiting

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

Conditions: Acute Myeloid Leukemia
NCT04378647

Not yet recruiting

BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant

Conditions: Hodgkin Lymphoma, Adult
NCT04375631

Not yet recruiting

CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome; Refractory Acute Leukemia of Ambiguous Lineage; Refractory Acute Undifferentiated Leukemia
NCT04373395

Recruiting

Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia
NCT04354025

Not yet recruiting

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Conditions: Refractory Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia
NCT04342936

Not yet recruiting

Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Conditions: Classical Hodgkin Lymphoma
NCT04330820

Recruiting

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

Conditions: Relapsed Adult AML
NCT04326439

Recruiting

AflacLL1901 (CHOA-AML)

Conditions: Acute Myeloid Leukemia; AML, Childhood
NCT04306640

Recruiting

Impact of Cervical Lordosis Rehabilitation on Autonomic Nervous Function and Cervical Sensorimotor Control

Conditions: Chronic Nonspecific Neck Pain
NCT04293562

Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Conditions: Acute Myeloid Leukemia
NCT04275518

Recruiting

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Conditions: Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
NCT04269213

Recruiting

CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Secondary Acute Myeloid Leukemia; Therapy-Related Acute Myeloid Leukemia
NCT04263181

Recruiting

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndromes
NCT04254640

Not yet recruiting

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Conditions: Acute Myeloid Leukemia; Elderly Patients; Newly Diagnosed
NCT04250051

Not yet recruiting

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Myeloproliferative Neoplasm; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome
NCT04248595

Recruiting

Azacitidine Combined With Homoharringtonie in AML

Conditions: Acute Myeloid Leukemia
NCT04240002

Active, not recruiting

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
NCT04229979

Recruiting

GPS Compared With BAT in AML CR2/CR2p

Conditions: Acute Myeloid Leukemia
NCT04230239

Recruiting

Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia

Conditions: Newly Diagnosed Secondary or High Risk AML
NCT04231851

Not yet recruiting

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Conditions: Acute Myelogenous Leukemia (AML) Due to Therapy; Acute Myeloid Leukemia With Myelodysplasia-Related Changes
NCT04220684

Recruiting

Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Allogeneic Stem Cell Transplant Recipient; Blasts 10 Percent or More of Bone Marrow Nucleated Cells; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT04216771

Recruiting

Comparing the Consolidation Regimens of IDA With Intermediate-dose Cytarabine Versus Intermediate-dose Cytarabine Alone for Elderly AML Patients

Conditions: AML in Remission
NCT04217278

Recruiting

A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Conditions: Acute Myeloid Leukaemia; Myelodysplasia
NCT04214249

Not yet recruiting

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT04216355

Recruiting

Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

Conditions: MDS-EB
NCT04216524

Recruiting

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
NCT04211987

Recruiting

Fast Track Total Hip Arthroplasty vs Standard Care

Conditions: Hip Osteoarthritis; Hip Pain Chronic
NCT04209725

Recruiting

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Conditions: Leukemia, Myeloid, Acute
NCT04195945

Recruiting

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Conditions: Acute Myeloid Leukemia; Myeloid Neoplasm
NCT04196010

Recruiting

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Conditions: Myeloid Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT04190550

Not yet recruiting

Testing a New Chemotherapy Drug, KRT-232 (AMG 232) in Combination With Standard Chemotherapy (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
NCT04179929

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

Conditions: Acute Lymphoblastic Leukemia
NCT04178343

Completed

Tomotherapy for Leptomeningeal Metastases

Conditions: Leptomeningeal Metastasis
NCT04173585

Recruiting

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

Conditions: Acute Myeloid Leukemia
NCT04174612

Not yet recruiting

AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
NCT04168138

Recruiting

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Conditions: Acute Myeloid Leukemia
NCT04168502

Not yet recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Conditions: Acute Myeloid Leukemia
NCT04158739

Recruiting

Flotetuzumab for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Conditions: Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT04134247

Not yet recruiting

Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With RR NHL

Conditions: Relapsed/Refractory Non-Hodgkin's Lymphoma
NCT04128748

Not yet recruiting

Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia; Blasts More Than 10 Percent of Bone Marrow Nucleated Cells; High Risk Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Myelodysplastic Syndrome
NCT04121819

Recruiting

AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis

Conditions: Langerhans Cell Histiocytosis
NCT04115631

Recruiting

A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma

Conditions: Liver Lymphoma; Mantle Cell Lymphoma
NCT04113616

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)